Navigation Links
IDM Pharma Announces UVIDEM(R) and EP-2101 Data Presentations at,2007 ASCO Annual Meeting

IRVINE, Calif., May 30, 2007 /PRNewswire-FirstCall/ -- IDM Pharma, Inc. today announced that data from a Phase II Uvidem melanoma vaccine clinical trial and data from the Phase II EP-2101 non-small cell lung cancer (NSCLC) vaccine clinical trial will be presented at the 2007 American Society of Clinical Oncology (ASCO) 43rd annual meeting in Chicago on June 1-5 2007.

    UVIDEM presentation details:


    --  "Clinical and immunological responses in patients with malignant

        melanoma treated with a dendritic cell-based vaccine. Preliminary

        report from a multi-institutional phase II clinical trial." Abstract

        # 3004, Session: Developmental Therapeutics: Immunotherapy. Oral

        presentation by Merrick I. Ross, M.D., Professor of Surgery, Chief,

        Melanoma Section, Department of Surgical Oncology at M. D. Anderson

        Cancer Center.

    --  June 5, 2007 at 7.45 AM

    --  Location: E354a



    EP-2101 presentation details:


    --  "Phase II trial of a 10-epitope CTL vaccine, EP-2101, in metastatic

        NSCLC patients." Abstract # 3068, Session: Developmental Therapeutics:

        Immunotherapy. Poster presentation.

    --  June 3, 2007, 8.00 AM - 12 PM

    --  Location: S Hall A2


About the UVIDEM(R) Clinical Trial

The U.S. clinical trial is designed to assess the safety and clinical activity of UVIDEM in patients with stage III or IV melanoma with measurable lesions. Participating centers include the University of California Los Angeles (UCLA) Jonsson Comprehensive Cancer Center, the MD Anderson Cancer Center, the University of Pittsburgh, the Arizona Cancer Center and Lutheran General Cancer Care Center

About the EP-2101 Clinical Trial

The U.S. clinical trial is designed to assess overall survival and vaccine safety, with vaccine immunogenicity as a secondary endpoint in HLA-A2+ patients with stage IIIb, IV or recurren
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Sygnis Pharma AG announces date for presentation of clinical results
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
Post Your Comments:
(Date:11/21/2014)... Md. , Nov. 21, 2014  The University ... will host the ceremonial groundbreaking of the new A. ... Park. The new building will cultivate transformative new engineering ... Taking place at 10:00 a.m. on November ... the Paint Branch Parking Lot, adjacent to the Jeong ...
(Date:11/21/2014)... SAN MARCOS, Texas , Nov. 21, 2014 /PRNewswire/ ... industrial hemp containing low THC, announces they are now ... is comparable to Charlotte,s Web type strains grown in ... symptoms from other neurological disorders, such as Parkinson,s, MS, ... waiting for US laws to pass, because imported CBD ...
(Date:11/21/2014)... , Nov. 21, 2014 ... the European Medicines Agency (EMA) has granted ... company,s lead product candidate, for the treatment ... a rare, severely disabling genetic disease characterized ... swelling (flare-ups) and new abnormal bone formation. ...
Breaking Medicine Technology:University of Maryland Breaks Ground for A. James Clark Hall 2University of Maryland Breaks Ground for A. James Clark Hall 3University of Maryland Breaks Ground for A. James Clark Hall 4New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 2New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 3Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 2Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 3
(Date:11/22/2014)... PITTSBURGH, PA (PRWEB) November 22, 2014 ... about the pain caused by the machine," said an ... injury, she had to go back a second time ... my invention idea." , She developed the patent-pending MAMO ... for breast cancer. The design saves the patient from ...
(Date:11/22/2014)... 22, 2014 Lipitor lawsuits ( http://www.lipitorlawsuitcenter.com/ ... who allegedly developed Type 2 diabetes due to its ... litigation now underway in U.S. District Court, District of ... documents, the litigation will convene its next Status Conference ... directed Lead Counsel for Plaintiffs and Defendants to meet ...
(Date:11/22/2014)... 22, 2014 The Sports Conflict Institute ... Baroff to its team of conflict resolution professionals. Baroff ... coach, and referee. He has over 30 years experience as ... , “I'm very excited to connect with SCI and bring ... interests to a program with a complete sports focus,” says ...
(Date:11/22/2014)... 2014 Wright & Schulte LLC reports ... have been scheduled between October 2016 and April ... Illinois. U.S. District Judge Matthew F. Kennelly, who is ... Order (CMO) on November 6, 2014 that outlined the ... submit documents and other activities in preparation for the ...
(Date:11/22/2014)... Steven Reinberg HealthDay Reporter ... are better when patients are treated in an ambulance by ... German researchers report. The sooner patients get the clot ... outcome after a stroke, the researchers noted. For the best ... hour after stroke symptoms start, the researchers said. "The ...
Breaking Medicine News(10 mins):Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 2Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 3Health News:SCI Announces New Team Member Roy Baroff 2Health News:SCI Announces New Team Member Roy Baroff 3Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 2Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 3Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 4Health News:Special Ambulance Delivers Vital Stroke Care More Quickly 2Health News:Special Ambulance Delivers Vital Stroke Care More Quickly 3
... By Amanda Gardner HealthDay Reporter , MONDAY, ... ubiquitous and pedestrian drugs -- aspirin -- may cut the ... has not yet spread beyond the gland, a new study ... 5,000 men with prostate cancer, 2,000 of whom were taking ...
... prostate cancer treated with a specialized type of ... fewer gastrointestinal complications compared to patients treated with ... study presented November 1, 2010, at the 52nd ... Oncology (ASTRO). , "With survivors living ...
... chemotherapy to radiation therapy for muscle invasive bladder cancer allows ... their bladders two years after treatment. This compares to 54 ... largest randomized study of its kind presented at the plenary ... the American Society for Radiation Oncology (ASTRO). , "The trial ...
... October 25, 2010 The Life Sciences Discovery Fund (LSDF) ... Corporation (NASDAQ: OMER) to discover, develop, and commercialize new ... successful generation of proceeds through partnering and the sales ... the grant would be establishment of a new non-profit ...
... By Serena Gordon HealthDay Reporter , MONDAY, Oct. ... to sleep-starved parents: Most infants will start sleeping through the ... may take a little longer, however, is for the baby,s ... schedule, according to the study. "The most rapid changes ...
... PICK: Pregnancy outcome affected by immune system genes ... Moffett, at the University of Cambridge, United Kingdom, has ... to and provide protection from common disorders of pregnancy, ... A key step in the initiation of a successful ...
Cached Medicine News:Health News:Aspirin May Help Patients Beat Prostate Cancer 2Health News:Aspirin May Help Patients Beat Prostate Cancer 3Health News:Highly targeted radiation technique minimizes side effects of prostate cancer treatment 2Health News:Chemotherapy plus radiation prevents bladder cancer recurrences 2Health News:Life Sciences Discovery Fund to support drug discovery, foster new R&D initiative 2Health News:Life Sciences Discovery Fund to support drug discovery, foster new R&D initiative 3Health News:Most Babies Start Sleeping Through Night at 2 to 4 Months 2Health News:Most Babies Start Sleeping Through Night at 2 to 4 Months 3Health News:JCI table of contents: Oct. 25, 2010 2Health News:JCI table of contents: Oct. 25, 2010 3Health News:JCI table of contents: Oct. 25, 2010 4Health News:JCI table of contents: Oct. 25, 2010 5Health News:JCI table of contents: Oct. 25, 2010 6Health News:JCI table of contents: Oct. 25, 2010 7Health News:JCI table of contents: Oct. 25, 2010 8Health News:JCI table of contents: Oct. 25, 2010 9
Surgical Drop-Off Apron...
All Day Comfort for the Upper Body...
All Day Comfort for the Upper Body...
Designed for special procedures, this Wrap-Around apron has .50mm Pb in the front and .25mm Pb in the back. The velcro fasteners are adjustable to provide the most comfortable fit....
Medicine Products: